Enanta Pharmaceuticals Inc (ENTA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jay R. Luly
Employees:
132
500 ARSENAL STREET, WATERTOWN, MA 02472
617 607 0800

Enanta Pharmaceuticals, Inc. engages in the research and development of small molecule drugs for the treatment of viral infections and liver diseases. It focuses on the following disease targets: Hepatitis C virus, Hepatitis B virus, Non-alcoholic Steatohepatitis, and Respiratory syncytial virus. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Data derived from most recent annual or quarterly report
Market Cap 1.028 Billion Shares Outstanding20.713 Million Avg 30-day Volume 307.773 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3.92
Price to Revenue15.9761 Debt to Equity0.0 EBITDA-127.247 Million
Price to Book Value4.0794 Operating Margin-143.97740000000002 Enterprise Value1.14 Billion
Current Ratio11.122 EPS Growth-0.511 Quick Ratio9.729
1 Yr BETA 0.8768 52-week High/Low 102.0 / 37.59 Profit Margin-122.6806
Operating Cash Flow Growth-128.761 Altman Z-Score18.2116 Free Cash Flow to Firm -92.727 Million
Earnings Report2022-08-04
View SEC Filings from ENTA instead.

View recent insider trading info

Enanta Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ENTA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ENTA BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-06-21 by MELLETT PAUL J
  • 4: filed on 2022-04-05 by ADDA NATHALIE
  • 4: filed on 2022-03-22 by CARTER BRUCE L A
  • 4: filed on 2022-03-07 by VANCE TERRY
  • 4: filed on 2022-03-07 by RUSSELL LESLEY
  • 4: filed on 2022-03-07 by PETERSON KRISTINE
  • 4: filed on 2022-03-07 by HATA YUJIRO S
  • 4: filed on 2022-03-07 by FOLETTA MARK G
  • 4: filed on 2022-03-07 by CARTER BRUCE L A
  • 4: filed on 2022-03-03 by ADDA NATHALIE

    • Events (8k)

  • 8-K: filed on 2022-06-22:
    Item 8.01: Other Events
  • 8-K: filed on 2022-05-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-08:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-22:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-08-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-07-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    3.5 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MELLETT PAUL J TREASURER AND CFO

    • Officer
    		 61,558 2022-06-17 4

    ADDA NATHALIE SR. VP & CHIEF MEDICAL OFFICER

    • Officer
    		 110,549 2022-04-01 8

    CARTER BRUCE L A

    • Director
    		 0 2022-03-21 2

    FOLETTA MARK G

    • Director
    		 7,500 2022-03-03 1

    RUSSELL LESLEY

    • Director
    		 7,500 2022-03-03 1

    PETERSON KRISTINE

    • Director
    		 7,500 2022-03-03 1

    VANCE TERRY

    • Director
    		 7,500 2022-03-03 1

    HATA YUJIRO S

    • Director
    		 7,500 2022-03-03 3

    LULY JAY R. PRESIDENT AND CEO

    • Officer
    		 716,464 2022-02-14 5

    OR YAT SUN SR. VP & CSO

    • Officer
    		 339,242 2022-02-14 3

    GARDINER NATHANIEL S. SR. VP & GENERAL COUNSEL

    • Officer
    		 67,213 2022-02-14 3

    KIEFFER TARA LYNN SR. VP, NEW PRODUCT DEV.

    • Officer
    		 7,864 2022-02-14 2

    LUU BRENDAN SR. VP, BUSINESS DEV.

    • Officer
    		 7,723 2022-02-14 2

    GOLUMBESKI GEORGE

    • Director
    		 0 2020-02-26 0

    BUCKLEY STEPHEN JR.

    • Director
    		 0 2019-02-28 0

    OCAIN TIM SENIOR VICE PRESIDENT

    • Officer
    		 17,547 2019-02-12 0

    AFTING ERNST-GUENTER

    • Director
    		 0 2016-02-11 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    MELLETT PAUL J - Officer TREASURER AND CFO

    		2022-06-21 16:01:24 -0400 2022-06-17 M 3,480 $11.77 a 61,558 direct 10.0747 13.0634 13.0634 6 0.0 1

    MELLETT PAUL J - Officer TREASURER AND CFO

    		2022-06-21 16:01:24 -0400 2022-06-17 M 3,480 d 0 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 22:15:04 UTC 1.1605 0.4095 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 21:45:03 UTC 1.1605 0.4095 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 21:15:03 UTC 1.1605 0.4095 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 20:45:03 UTC 1.1605 0.4095 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 20:15:03 UTC 1.1605 0.4095 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 19:45:03 UTC 1.1605 0.4095 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 19:15:03 UTC 1.1605 0.4095 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 18:45:03 UTC 1.1602 0.4098 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 18:15:03 UTC 1.1602 0.4098 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 17:45:03 UTC 1.1602 0.4098 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 17:15:03 UTC 1.1602 0.4098 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 16:45:03 UTC 1.1611 0.4089 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 16:15:03 UTC 1.1611 0.4089 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 15:45:04 UTC 1.1611 0.4089 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 15:15:03 UTC 1.1611 0.4089 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 14:45:03 UTC 1.1611 0.4089 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 14:15:03 UTC 1.1611 0.4089 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 13:45:03 UTC 1.1604 0.4096 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 13:15:03 UTC 1.1604 0.4096 650000
    ENANTA PHARMACEUTICALS INC ENTA 2022-07-01 12:45:03 UTC 1.1604 0.4096 650000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments